Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Valuation and Earnings
This table compares Lexaria Bioscience and Collegium Pharmaceutical”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lexaria Bioscience | $194,000.00 | 43.75 | -$11.90 million | ($5.10) | -0.79 |
| Collegium Pharmaceutical | $780.57 million | 0.98 | $62.87 million | $1.00 | 24.72 |
Collegium Pharmaceutical has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for Lexaria Bioscience and Collegium Pharmaceutical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lexaria Bioscience | 1 | 0 | 1 | 0 | 2.00 |
| Collegium Pharmaceutical | 0 | 2 | 7 | 1 | 2.90 |
Lexaria Bioscience presently has a consensus target price of $22.50, suggesting a potential upside of 458.31%. Collegium Pharmaceutical has a consensus target price of $44.00, suggesting a potential upside of 77.99%. Given Lexaria Bioscience’s higher possible upside, research analysts plainly believe Lexaria Bioscience is more favorable than Collegium Pharmaceutical.
Institutional & Insider Ownership
13.1% of Lexaria Bioscience shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 1.9% of Collegium Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Lexaria Bioscience and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lexaria Bioscience | N/A | -174.93% | -143.89% |
| Collegium Pharmaceutical | 4.68% | 85.14% | 13.80% |
Volatility and Risk
Lexaria Bioscience has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
Summary
Collegium Pharmaceutical beats Lexaria Bioscience on 11 of the 15 factors compared between the two stocks.
About Lexaria Bioscience
Lexaria Bioscience is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics. The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments.
About Collegium Pharmaceutical
Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
